Adrenocorticotropic Hormone (ACTH), also known as Corticotropin or Acthar, is an endogenous peptide hormone produced by the anterior pituitary gland. It belongs to the chemical class of polypeptide hormones. ACTH is synthesized from the precursor molecule pro-opiomelanocortin (POMC) and plays a crucial role in the stress response. Synthetic forms of ACTH are used in clinical settings for diagnostic and therapeutic purposes.
ACTH primarily stimulates the adrenal cortex to secrete glucocorticoids, particularly cortisol, which is vital for metabolism and immune response modulation. Researchers have found that ACTH is involved in the regulation of circadian rhythms and stress adaptation. It is also a focus of research in conditions such as Addison's disease, Cushing's syndrome, and congenital adrenal hyperplasia.
The mechanism of action of ACTH involves binding to the melanocortin 2 receptor (MC2R) on adrenal cortical cells. This interaction activates the adenylate cyclase-cAMP pathway, leading to increased steroidogenesis and cortisol production. Researchers have observed that this pathway is crucial for maintaining homeostasis under stress.
Pharmacokinetically, endogenous ACTH has a circulating half-life of approximately 10 minutes. It is rapidly metabolized by enzymes in the liver and kidneys. Synthetic forms, such as depot injections, have modified pharmacokinetics to prolong their action. Bioavailability varies with the route of administration, with intravenous administration providing immediate effects.
Clinically, ACTH is used in diagnostic tests for adrenal insufficiency and as a therapeutic agent in certain inflammatory and autoimmune conditions. In the United States, ACTH is FDA-approved for specific indications. Regulatory standing varies by country, with prescription requirements in place to ensure appropriate use. Researchers continue to explore its potential in various therapeutic areas.